ALK and angioimmunoblastic T-cell lymphoma: In a cohort of 86 patients (PTCL: n = 33, TFH inclusive of AITL: n = 31, ALK-negative ALCL: n = 21, unclassifiable: n = 1) the 18-month PFS was 48%, which did not meet the planned statistical threshold for study continuation, and enrollment was stopped [42].